Product Description: CIB-L43 is an orally active TRBP inhibitor (KD = 4.78 nM) and enhances disruption of TRBP-Dicer interactions (IC50 = 2.34 μM). CIB-L43 suppresses oncogenic miR-21 biosynthesis, increasing PTEN and Smad7 expression and inhibiting AKT and TGF-β signaling, thereby reducing HCC cell proliferation and migration[1].
Formula: C15H16N2O3S
References: [1]Shi H, et al. Design, Synthesis, and Antitumor Activity Evaluation of 2-Phenylthiazole-5-Carboxylic Acid Derivatives Targeting Transactivation Response RNA-Binding Protein 2. J Med Chem. 2025 Jan 9;68(1):421-447.
CAS Number: 1082942-70-8
Molecular Weight: 304.36
Compound Purity: 99.71
Research Area: Cancer
Solubility: DMSO : 8.93 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Akt;PTEN;TGF-beta/Smad